Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | HPGD | P15428 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.83 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30319723 | 1.00 | ALDH1A1 (0.83) | ALDH1A1CYP3A4ABCG2KDM4EHPGD | |
| SCHEMBL18106040 | 1.00 | ALDH1A1 (0.83) | ALDH1A1CYP3A4ABCG2KDM4EHPGD | |
| SCHEMBL5085603 | 0.91 | CYP19A1 (0.82) | ALDH1A1CYP3A4ABCG2KDM4EHPGD | |
| Dimethylpinocembrin SCHEMBL2879027 | 0.91 | ABCG2 (1.00) | ALDH1A1CYP3A4ABCG2KDM4EHPGD | |
| SCHEMBL18104378 | 0.90 | ALDH1A1 (0.68) | ALDH1A1CYP3A4ABCG2KDM4EHPGD | |
| SCHEMBL12067056 | 0.90 | ALDH1A1 (0.80) | ALDH1A1CYP3A4ABCG2KDM4EHPGD | |
| SCHEMBL18104369 | 0.90 | ALDH1A1 (0.68) | ALDH1A1CYP3A4ABCG2KDM4EHPGD | |
| SCHEMBL5857357 | 0.90 | ALDH1A1 (0.76) | ALDH1A1CYP3A4ABCG2KDM4EHPGD | |
| Alpinetin SCHEMBL30741428 | 0.89 | CYP1A1 (0.80) | ALDH1A1CYP3A4ABCG2KDM4EHPGD | |
| Alpinetin SCHEMBL29844118 | 0.89 | CYP1A1 (0.80) | ALDH1A1CYP3A4ABCG2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4153558-B1 | A METHOD FOR SYNTHESIZING XANTHOHUMOL | PROXN SP Z O O (PL) | 2023-08-02 | — | — | EP | disclosed |
| CN-114224880-B | Application of 5,7,4' -trimethoxyflavone in preparing medicine for preventing and treating tumor | 中美（河南）荷美尔肿瘤研究院 | 2023-04-11 | — | — | CN | disclosed |
| US-20210228672-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2021-07-29 | — | — | US | disclosed |
| US-10918687-B2 | Kava derived therapeutic compounds and methods of use thereof | KUALITY HERBCEUTICS LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10624943-B2 | Kava derived therapeutic compounds and methods of use thereof | Kuality Herbceutics, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-10435673-B2 | Method for the biotechnological production of flavonoids | SYMRISE AG (DE) | 2019-10-08 | — | — | US | disclosed |
| US-20180135029-A1 | METHOD FOR THE BIOTECHNOLOGICAL PRODUCTION OF FLAVONOIDS | SYMRISE AG (DE) | 2018-05-17 | — | — | US | disclosed |
| US-20180135029-A1 | METHOD FOR THE BIOTECHNOLOGICAL PRODUCTION OF FLAVONOIDS | SYMRISE AG (DE) | 2018-05-17 | — | — | US | disclosed |
| US-20170107242-A1 | NOVEL FLAVONOIDS O-A-GLUCOSYLATED ON THE B CYCLE, METHOD FOR THE PRODUCTION THEREOF AND USES | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2017-04-20 | — | — | US | disclosed |
| US-20160279184-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2016-09-29 | — | — | US | disclosed |
| EP-3002335-A1 | Process for the biotechnological production of flavonoids | Symrise AG (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-7638554-B2 | Flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents | SRI INTERNATIONAL (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638554-B2 | Flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents | SRI INTERNATIONAL (US) | 2009-12-29 | — | — | US | disclosed |
| US-7329687-B2 | Flavanoid compounds as chemotherapeutic, chemopreventive, and antiangiogenic agents | SRI INTERNATIONAL (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329687-B2 | Flavanoid compounds as chemotherapeutic, chemopreventive, and antiangiogenic agents | SRI INTERNATIONAL (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329687-B2 | Flavanoid compounds as chemotherapeutic, chemopreventive, and antiangiogenic agents | SRI INTERNATIONAL (US) | 2008-02-12 | — | — | US | disclosed |
| US-6677350-B1 | ADMINISTERING CHALCONE-LIKE VINYLCARBONYL COMPOUNDS TO PREVENT OR TREAT MYCOBACTERIUM INFECTIONS/TUBERCULOSIS | ADVANCED LIFE SCIENCES, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030229136-A1 | Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents | SRI INTERNATIONAL | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107242-A1 | NOVEL FLAVONOIDS O-A-GLUCOSYLATED ON THE B CYCLE, METHOD FOR THE PRODUCTION THEREOF AND USES | UGGT1, ENGASE, OGA | ALDH1A1 2778/4885CYP3A4 215/4885ABCG2 753/4885 |
| US-20210228672-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KLK5, KLK4, KLK2 | ALDH1A1 1649/4885CYP3A4 745/4885ABCG2 3744/4885 |
| US-20030229136-A1 | Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents | FLT1, VEGFA, FLT4 | ALDH1A1 154/4885CYP3A4 336/4885ABCG2 245/4885 |
| US-10918687-B2 | Kava derived therapeutic compounds and methods of use thereof | KLK5, KLK4, KLK2 | ALDH1A1 1649/4885CYP3A4 745/4885ABCG2 3744/4885 |
| US-20160279184-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KLK5, KLK4, KLK2 | ALDH1A1 1649/4885CYP3A4 745/4885ABCG2 3744/4885 |
| US-10624943-B2 | Kava derived therapeutic compounds and methods of use thereof | KLK5, KLK4, KLK2 | ALDH1A1 1649/4885CYP3A4 745/4885ABCG2 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.